{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-087020","form_type":"8-K","ticker":null,"cik":"0001061027","company_name":"Viracta Therapeutics, Inc.","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.060849+00:00","generated_at":"2026-05-31T15:37:14.585953+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viracta Therapeutics cuts ~23% of workforce; expects $0.7M severance costs","bullets":["Reduction in force approved July 22, 2024, affecting ~23% of employees.","Completion expected in August 2024.","Estimated $0.7M in severance and healthcare benefits expenses.","Company may incur additional charges not currently anticipated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-087020","json":"https://secwatch.observer/filing/0000950170-24-087020.json","markdown":"https://secwatch.observer/filing/0000950170-24-087020.md","text":"https://secwatch.observer/filing/0000950170-24-087020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024087020/0000950170-24-087020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024087020/virx-20240722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:37:14.585953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67b712089d8143594be3c58d007ece411fd679cc","claim":"Viracta Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million (approximately 23% of the Company’s workforce).","evidence_excerpt":"and implemented a reduction in force, to be completed in August 2024, that impacted approximately 23% of the Company’s workforce. The Company expects to recognize approximately $0.7 million in total expenses for severance and related benefits for employees laid off under the reduction in force, consisting primarily of severance payments and continued healthcare","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024087020/0000950170-24-087020-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.7 million"},{"label":"Headcount","value":"approximately 23% of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}